Loading...
•
Dec 31, 2024
Ultragenyx Q4 2024 Earnings Report
Ultragenyx reported strong revenue growth in Q4 2024, driven by key product sales, but continued to post a net loss.
Key Takeaways
Ultragenyx delivered $164,877,000 in revenue for Q4 2024, a 29% YoY increase, primarily fueled by Crysvita and Dojolvi sales. Despite higher revenue, the company reported a net loss of $133,385,000, with increased R&D and operating expenses.
Total revenue grew 29% YoY to $164,877,000.
Crysvita and Dojolvi saw strong revenue growth of 23% and 34% YoY, respectively.
Net loss narrowed to $133,385,000, despite increased operating expenses.
2025 guidance projects revenue growth of 14-20% YoY.
Ultragenyx
Ultragenyx
Ultragenyx Revenue by Segment
Ultragenyx Revenue by Geographic Location
Revenue by Segment
Crysvita Revenue
CapyFin.comDojolvi Revenue
CapyFin.comEvkeeza Revenue
CapyFin.comMepsevii Revenue
CapyFin.comRevenue by Geographic Location
Europe Revenue
CapyFin.com Forward Guidance
Ultragenyx expects 2025 revenue growth of 14-20%, with focused investments in commercial launches and late-stage clinical programs.
Positive Outlook
- Total revenue projected to reach $640M-$670M.
- Crysvita revenue expected to grow to $460M-$480M.
- Dojolvi revenue guidance set at $90M-$100M.
- Expense management prioritized to reduce net cash burn.
- Multiple late-stage clinical trials progressing as planned.
Challenges Ahead
- Net losses likely to continue despite revenue growth.
- Higher R&D and SG&A expenses expected to persist.
- Regulatory uncertainties around gene therapy approvals.
- Dependence on partner collaborations for key products.
- Potential market challenges in expanding product adoption.